Molecular features of the prazosin molecule required for activation of Transport-P

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 15, 2008, Pages 7254-7263

  da Silva, Joaquim Fernando Mendes ^a,b   Walters, Marcus ^a   Al Damluji, Saad ^c   Ganellin, C Robin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Amine uptake; Antidepressant; Furan; Peptidergic neurones; Prazosin; Quinazoline; Transport P

Indexed keywords

4 (4 AMINO 6,7 DIMETHOXYQUINAZOLIN 2 YL)PIPERAZINE 1 CARBOXYLIC ACID BENZYLESTER HYDROCHLORIDE; 4 ACETAMIDO 6,7 DIMETHOXY 2 [4 (2-FUROYL)PIPERAZIN 1 YL]QUINAZOLINE; 4 AMINO 6,7 DIMETHOXY 2 (4 TRIFLUOROACETYLPIPERAZIN 1 YL)QUINAZOLINE HYDROCHLORIDE; 4 AMINO 6,7 DIMETHOXY 2 (FURFURYLAMINO)QUINAZOLINE HYDROCHLORIDE; 4 AMINO 6,7 DIMETHOXY 2 [2 FUROYL 4 (1,4 DIAZEPAN 1 YL)]QUINAZOLINE; 4 AMINO 6,7 DIMETHOXY 2 [4 (2 THIOPHENE CARBONYL)PIPERAZIN 1 YL]QUINAZOLINE HYDROCHLORIDE HYDRATE; 4 AMINO 6,7 DIMETHOXY 2 [N (2 AMINOETHYL)PIPERIDINYL]QUINAZOLINE DIHYDROCHLORIDE; 4 AMINO 6,7 DIMETHOXY 4 (2 TETRAHYDROFURANOYLIPERAZIN 1 YL)QUINAZOLINE HYDROCHLORIDE MONOHYDRATE; 4 BENZYLAMINO 6,7 DIMETHOXY 2 [4 (2-FUROYL)PIPERAZIN 1 YL]QUINAZOLINE HYDROCHLORIDE; 6,7 DIMETHOXY 4 METHYLAMINO 2 [4 (2-FUROYL)PIPERAZIN 1 YL]QUINAZOLINE HYDROCHLORIDE; 6,7 DIMETHOXY 4 PHENYLAMINO 2 [4 (2 FUROYL)PIPERAZIN 1 YL]QUINAZOLINE HYDROCHLORIDE; [4 (4 AMINO 7,8 DIHYDRO[1,4]DIOXINO[2,3G]QUINAZOLIN 2 YL)PIPERAZIN 1 YL]FURAN 2 YL METHANONE HYDROCHLORIDE; DESIPRAMINE; PRAZOSIN; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

AMINE TRANSPORT; ARTICLE; DRUG INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG UPTAKE; HUMAN; HUMAN CELL; MEMBRANE TRANSPORT; MOLECULE; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION; TRANPORT P;

ANTIHYPERTENSIVE AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CELLS, CULTURED; MOLECULAR STRUCTURE; NEURONS; PRAZOSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 48449093456     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2008.06.037     Document Type: Article

References (22)

1. Al-Damluji S., Krsmanovic L.Z., and Catt K.J. Br. J. Pharmacol. 109 (1993) 299
2. Al-Damluji S., and Kopin I.J. Br. J. Pharmacol. 117 (1996) 111
3. Al-Damluji S., Porter D., Krsmanovic L.Z., Knutson J.R., and Kopin I.J. Br. J. Pharmacol. 120 (1997) 876
4. Al-Damluji S., Shen W.B., White S., and Barnard E.A. Br. J. Pharmacol. 132 (2001) 336
5. Al-Damluji S., and Kopin I.J. Br. J. Pharmacol. 117 (1996) 811
6. Campbell S.F., Davey M.J., Hardstone J.D., Lewis B.N., and Palmer M.J. J. Med. Chem. 30 (1987) 49
7. Al-Damluji S., and Kopin I.J. Br. J. Pharmacol. 124 (1998) 693
8. Al-Damluji, S.; Ganellin, C. R. Abstracts of Papers, British Pharmacological Society Meeting, April 2002, Hatfield, UK Br. J. Pharmacol., 2002, 136, 20 p.
9. Al-Damluji S. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 201
10. Zunszain P.A., Federico C., Sechi M., Al-Damluji S., and Ganellin C.R. Bioorg. Med. Chem. 13 (2005) 3681
11. Althuis T.H., and Hess H.-J. J. Med. Chem. 20 (1977) 146
12. Titmarsh S., and Monk J.P. Drugs 33 (1987) 461
13. Roteman, R. U.S. Patent, 4,251,532, 1981 to Abbott Laboratories
14. Xu D., Prasad K., Repic O., and Blacklock T.J. Tetrahedron Lett. 36 (1995) 7357
15. Goldman L., and Williams J.H. J. Org. Chem. 18 (1953) 815
16. Hess H.-J., Cronin T.H., and Scriabine A. J. Med. Chem. 11 (1968) 130
17. Cava M.P., and Dalton D.R. J. Org. Chem. 31 (1966) 1281
18. Hess, H. J. U.S. Patent, 3,511,836 (1970), 3, 935,213 (1973).
19. Honkanen E., Pippuri A., Kairisalo P., Thaler H., Koivisto M., and Tuomi S. J. Heterocycl. Chem. 17 (1980) 797
20. Curd F.H.S., Landquist J.K., and Rose F.L. J. Chem. Soc. (1948) 1759
21. Millen J., Riley T.N., Waters I.W., and Hamrick M.E. J. Med. Chem. 28 (1985) 12
22. Al-Damluji S., and Shen W.B. Br. J. Pharmacol. 132 (2001) 851